Sell 10/23/2023Downgrade
Acrivon Therapeutics, Inc. (ACRV) was downgraded to E+ from D- on 10/23/2023 due to a major decline in the efficiency index, growth index and total return index. Net income declined 9.08% from -$12.76M to -$13.91M, earnings per share declined from -$0.5819 to -$0.6333, and EBIT declined 7.83% from -$14.39M to -$15.52M.

Sell 8/1/2023Upgraded
Acrivon Therapeutics, Inc. (ACRV) was upgraded to D- from E on 08/01/2023.

Sell 5/31/2023Downgrade
Acrivon Therapeutics, Inc. (ACRV) was downgraded to E from E+ on 5/31/2023 due to a decline in the volatility index, solvency index and total return index.

Sell 5/1/2023Upgraded
Acrivon Therapeutics, Inc. (ACRV) was upgraded to E+ from E on 5/1/2023 due to a significant increase in the solvency index and total return index. The quick ratio increased from 12.02 to 19.61.

Sell 2/10/2023None
Acrivon Therapeutics, Inc. (ACRV) was downgraded to E from U on 02/10/2023.